Ladan Zand is a Nephrology physician affiliated with Mayo Clinic. OpenAlex indexes 164 publications with 4,309 citations (h-index 38); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 1st St SW
Rochester, MN 559050001
Telephone
507-284-2511Provider last certified this registry record 16 Feb 2021.
Clinical trials
- Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
Sponsor: Mayo Clinic
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20256 payments
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year20252 payments
- Travere Therapeutics, Inc.Program year20249 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
75%Calcium channel blocker18.5%Amlodipine Besylate100%Part D≥14 patientsLoop diuretic17.5%Torsemide60%Furosemide40%Part D<11 patients+ 4 more classes in this area
Anti-infectives
10.5%Short-acting sulfonamides10.5%Sulfamethoxazole-Trimethoprim100%Part D≥11 patientsOther
8%Drugs for treatment of hyperkalemia and hyperphosphatemia8%Lokelma100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Histologic and Clinical Factors Associated with Kidney Outcomes in IgA Vasculitis Nephritis
Clinical Journal of the American Society of Nephrology
2024 - Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification
Kidney International
2023 - Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy
Clinical Journal of the American Society of Nephrology
2023 - Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification
Mayo Clinic Proceedings
2023
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Rick Nishimura, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”